Disease severity-based subgrouping of type 2 diabetes does not parallel differences in quality of life: the Maastricht Study.
| Autor: | Werkman NCC; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, the Netherlands., García-Sáez G; Bioengineering and Telemedicine Group, Centro de Tecnología Biomédica, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain.; Centro de Investigación Biomédica en Red (CIBER)-BBN: Networking Research Center for Bioengineering, Biomaterials and Nanomedicine, Madrid, Spain., Nielen JTH; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands. yannick.nielen@mumc.nl.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, the Netherlands. yannick.nielen@mumc.nl., Tapia-Galisteo J; Bioengineering and Telemedicine Group, Centro de Tecnología Biomédica, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain.; Centro de Investigación Biomédica en Red (CIBER)-BBN: Networking Research Center for Bioengineering, Biomaterials and Nanomedicine, Madrid, Spain., Somolinos-Simón FJ; Bioengineering and Telemedicine Group, Centro de Tecnología Biomédica, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain., Hernando ME; Bioengineering and Telemedicine Group, Centro de Tecnología Biomédica, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain.; Centro de Investigación Biomédica en Red (CIBER)-BBN: Networking Research Center for Bioengineering, Biomaterials and Nanomedicine, Madrid, Spain., Wang J; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Jiu L; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Goettsch WG; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.; National Health Care Institute, Diemen, the Netherlands., van der Kallen CJH; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.; Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands., Koster A; Department of Social Medicine, Maastricht University, Maastricht, the Netherlands.; School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, the Netherlands., Schalkwijk CG; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.; Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands., de Vries H; Department of Epidemiology, Maastricht University, Maastricht, the Netherlands., de Vries NK; School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, the Netherlands., Eussen SJPM; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.; School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, the Netherlands.; Department of Epidemiology, Maastricht University, Maastricht, the Netherlands., Driessen JHM; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, the Netherlands., Stehouwer CDA; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.; Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Diabetologia [Diabetologia] 2024 Apr; Vol. 67 (4), pp. 690-702. Date of Electronic Publication: 2024 Jan 11. |
| DOI: | 10.1007/s00125-023-06082-4 |
| Abstrakt: | Aims/hypothesis: Type 2 diabetes is a highly heterogeneous disease for which new subgroups ('clusters') have been proposed based on disease severity: moderate age-related diabetes (MARD), moderate obesity-related diabetes (MOD), severe insulin-deficient diabetes (SIDD) and severe insulin-resistant diabetes (SIRD). It is unknown how disease severity is reflected in terms of quality of life in these clusters. Therefore, we aimed to investigate the cluster characteristics and cluster-wise evolution of quality of life in the previously defined clusters of type 2 diabetes. Methods: We included individuals with type 2 diabetes from the Maastricht Study, who were allocated to clusters based on a nearest centroid approach. We used logistic regression to evaluate the cluster-wise association with diabetes-related complications. We plotted the evolution of HbA Results: We included 127 newly diagnosed and 585 already diagnosed individuals. Already diagnosed people in the SIDD cluster were less likely to reach glycaemic control than people in the other clusters, with an HR compared with MARD of 0.31 (95% CI 0.22, 0.43). There were few differences in the mental component score of the SF-36 in both newly and already diagnosed individuals. In both groups, the MARD cluster had a higher physical component score of the SF-36 than the other clusters, and the MOD cluster scored similarly to the SIDD and SIRD clusters. Conclusions/interpretation: Disease severity suggested by the clusters of type 2 diabetes is not entirely reflected in quality of life. In particular, the MOD cluster does not appear to be moderate in terms of quality of life. Use of the suggested cluster names in practice should be carefully considered, as the non-neutral nomenclature may affect disease perception in individuals with type 2 diabetes and their healthcare providers. (© 2024. The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink